28449-15-2 Usage
Description
(6beta)-6-hydroxypregn-4-ene-3,11,20-trione is a steroidal chemical compound derived from pregnenolone, featuring a unique structure with three fused cyclohexane rings and ketone groups at carbon 3, 11, and 20. It plays a role in various biological processes and has been studied for its potential pharmacological activities, such as anti-inflammatory, immunomodulatory, and neuroprotective properties. (6beta)-6-hydroxypregn-4-ene-3,11,20-trione also acts as a precursor for the synthesis of other hormones and steroid molecules in the body and has been investigated for therapeutic applications in autoimmune diseases, hormonal disorders, and neurodegenerative diseases.
Uses
Used in Pharmaceutical Industry:
(6beta)-6-hydroxypregn-4-ene-3,11,20-trione is used as a precursor for the synthesis of other hormones and steroid molecules, which are essential for various physiological functions in the human body. Its role in hormone synthesis makes it a valuable compound in the development of treatments for hormonal disorders.
Used in Anti-inflammatory Applications:
Due to its anti-inflammatory properties, (6beta)-6-hydroxypregn-4-ene-3,11,20-trione is used as a potential therapeutic agent for conditions characterized by inflammation, such as autoimmune diseases. It may help modulate the immune response and reduce inflammation, providing relief from symptoms and potentially slowing disease progression.
Used in Neurodegenerative Disease Treatment:
(6beta)-6-hydroxypregn-4-ene-3,11,20-trione is used as a potential therapeutic agent for neurodegenerative diseases due to its neuroprotective properties. It may help protect neurons from damage and promote neuronal health, potentially slowing the progression of conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Used in Immunomodulatory Applications:
As an immunomodulatory agent, (6beta)-6-hydroxypregn-4-ene-3,11,20-trione is used to modulate the immune system's response, which can be beneficial in treating autoimmune diseases where the immune system mistakenly attacks the body's own tissues. By regulating the immune response, this compound may help reduce the severity of symptoms and improve the quality of life for patients with autoimmune conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 28449-15-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,4,4 and 9 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 28449-15:
(7*2)+(6*8)+(5*4)+(4*4)+(3*9)+(2*1)+(1*5)=132
132 % 10 = 2
So 28449-15-2 is a valid CAS Registry Number.
28449-15-2Relevant articles and documents
Effects of Alternative Redox Partners and Oxidizing Agents on CYP154C8 Catalytic Activity and Product Distribution
Dangi, Bikash,Park, Hyun,Oh, Tae-Jin
, p. 2273 - 2282 (2018)
CYP154C8 catalyzes the hydroxylation of diverse steroids, as has previously been demonstrated, by using an NADH-dependent system including putidaredoxin and putidaredoxin reductase as redox partner proteins carrying electrons from NADH. In other reactions, CYP154C8 reconstituted with spinach ferredoxin and NADPH-dependent ferredoxin reductase displayed catalytic activity different from that of the NADH-dependent system. The NADPH-dependent system showed multistep oxidation of progesterone and other substrates including androstenedione, testosterone, and nandrolone. (Diacetoxyiodo)benzene was employed to generate compound I (FeO3+), actively supporting the redox reactions catalyzed by CYP154C8. In addition to 16α-hydroxylation, progesterone and 11-oxoprogesterone also underwent hydroxylation at the 6β-position in reactions supported by (diacetoxyiodo)benzene. CYP154C8 was active in the presence of high concentrations (>10 mm) of H2O2, with optimum conversion surprisingly being achieved at ≈75 mm H2O2. More importantly, H2O2 tolerance by CYP154C8 was evident in the very low heme oxidation rate constant (K) even at high concentrations of H2O2. Our results demonstrate that alternative redox partners and oxidizing agents influence the catalytic efficiency and product distribution of a cytochrome P450 enzyme. More importantly, these choices affected the type and selectivity of reaction catalyzed by the P450 enzyme.
